AMP Therapeutics was founded in 2009 as a spin-out of Prof. Ralf Hoffmann’s laboratory at the University of Leipzig. In 2011, AMPT raised funds in a Series A Financing Round from renowned international life science investors Boehringer Ingelheim Venture Fund and Novartis Venture Funds.
High unmet medical need for new antibiotics against Gram-negative pathogens
- More than 25,000 patients die every year in Europe alone by infections acquired during hospital stays caused by bacterial and viral pathogens.
- It has been estimated that approximately 30-40% of all hospital-acquired (nosocomial) infections worldwide are caused by Gram-negative bacteria.
- In many cases the causative agents are (multi)drug-resistant variants of Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumoniae.
- Gram-negative pathogens are highly genetically flexible and thus develop resistance mechanisms that render most of the current therapies ineffective.
- Today there are less than a handful of approved antibiotics available to combat acute Gram-negative infections. Their use is limited by their significant toxic potential
- The pharmaceutical industry’s clinical development pipeline in this sector is virtually empty for the next ten to twelve years.
- The Infectious Diseases Society of America has calculated that the development of 10 new antibiotics by 2020 is required to adequately combat resistant bacteria.